RT Journal Article
SR Electronic
T1 One-Step Rapid Quantification of Serum Neutralizing Antibody after COVID-19 Vaccination by a High-Throughput Nanoplasmonic Sensor Platform
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.21.21255838
DO 10.1101/2021.04.21.21255838
A1 Huang, Liping
A1 Li, Ying
A1 Changyou, Luo
A1 Touil, Nadia
A1 Annaz, Hicham el
A1 Cheng, Youqian
A1 Zeng, Shaoqi
A1 Dang, Tang
A1 Liang, Jiawei
A1 Hu, Wenjun
A1 Xu, Hao
A1 Tu, Jiasheng
A1 Shen, Yan
A1 Liu, Gang L.
YR 2021
UL http://medrxiv.org/content/early/2021/04/27/2021.04.21.21255838.abstract
AB The COVID-19 vaccination efficacy depends on serum production level of the neutralizing IgG antibody (NA) specific to the receptor binding domain of SARS-Cov-2 spike protein. Therefore, a high-throughput rapid assay to measure the total SARS-CoV-2 NA level is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, vaccine development, and assessment. Here, we developed a nanoplasmonic immunosorbent assay (NanoPISA) platform for one-step rapid quantification of SARS-CoV-2 NAs in clinical serum samples for high-throughput evaluation of COVID-19 vaccine effectiveness. The NanoPISA platform enhanced by the use of nanoporous hollow gold nanoparticle coupling was able to detect SARS-CoV-2 NAs with a limit of detection of 0.1 ng/mL within 15 min. The one-step NanoPISA for SARS-CoV-2 NA detection in clinical specimens yielded good results, comparable to those obtained in the gold standard seroneutralization test and the surrogate virus neutralizing ELISA. Collectively, our findings indicate that the one-step NanoPISA may offer a rapid and high-throughput NA quantification platform for evaluating the effectiveness of COVID-19 vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from the National Key R & D Plan of China (2020YFC0861900), the National Natural Science Foundation of China (91959107, 81972892) and Fundamental Research Funds for the Central Universities (2020kfyXGYJ111).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the Science and Technology Department of Huazhong University of Science and Technology (Certificate #: S1029).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are available from the authors.